Brain tumor

CNS Announces Common Stock Will Resume Trading on the NASDAQ on May 28, 2020

Wednesday, May 27, 2020 - 11:00pm

HOUSTON, May 27, 2020 /PRNewswire/ --CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has received notification from Nasdaq that trading in the Company's common stock will resume on Thursday, May 28, 2020.

Key Points: 
  • HOUSTON, May 27, 2020 /PRNewswire/ --CNS Pharmaceuticals, Inc., (Nasdaq: CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it has received notification from Nasdaq that trading in the Company's common stock will resume on Thursday, May 28, 2020.
  • CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system.
  • Its lead drug candidate, Berubicin, is proposed for the treatment of GBM, an aggressive and incurable form of brain cancer.
  • This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders.

Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug

Wednesday, May 27, 2020 - 1:00pm

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the Company or Nascent) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.

Key Points: 
  • SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the Company or Nascent) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.
  • The PTB antibody is used as a targeted immunotherapy, which unlike chemotherapy, targets only the cancer cells without damaging healthy cells.
  • Our lead candidate, Pritumumab (PTB), is a monoclonal Antibody (Mab) that will be studied in Phase I clinical trials for the treatment of Brain Cancer.
  • These risks and uncertainties include, without limitation, Nascent Biotech Inc's ability to target the medical professionals; Nascent Biotech Inc's ability to raise capital; as well as other risks.

Art of Surviving, Global Online Art Exhibition, Launches in Honor of Brain Tumor Awareness Month

Sunday, May 24, 2020 - 6:00pm

Wood Foundation (RAWF) launches the third year of "Art of Surviving," a virtual art exhibition that celebrates the creativity of the brain tumor community during the month of May, which is Brain Tumor Awareness Month.

Key Points: 
  • Wood Foundation (RAWF) launches the third year of "Art of Surviving," a virtual art exhibition that celebrates the creativity of the brain tumor community during the month of May, which is Brain Tumor Awareness Month.
  • Wood Foundation helps improve quality of life for hypothalamic-pituitary brain tumor survivors by providing access to education, technology, and evolving treatments.
  • Many brain tumor survivors use art as a way to cope with the challenges that come with treatment, a means to calm and focus a healing brain, or an opportunity to express their experiences.
  • "I thought providing a platform for sharing artwork would be a positive thing for the foundation to do during Brain Tumor Awareness Month," said Wood.

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

Friday, May 22, 2020 - 9:30pm

We believe this approval for ALUNBRIG is a substantial step in the right direction and represents significant progress for Takedas broader lung cancer portfolio.

Key Points: 
  • We believe this approval for ALUNBRIG is a substantial step in the right direction and represents significant progress for Takedas broader lung cancer portfolio.
  • Twenty-nine percent of patients had brain metastases at baseline in the ALUNBRIG arm versus 30% in the crizotinib arm.
  • In the ALTA 1L trial, serious adverse reactions occurred in 33% of patients receiving ALUNBRIG.
  • In the ALUNBRIG arm of trial ALTA 1L (180 mg once daily), ILD/pneumonitis occurred in 5.1% of patients receiving ALUNBRIG.

Hoag is First in Nation to Test Innovative Antibody Brain Cancer Drug

Tuesday, May 19, 2020 - 7:29pm

Pritumumab is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ referred to as epithelial cells.

Key Points: 
  • Pritumumab is a unique monoclonal antibody that attacks cancers originating in the cells lining an organ referred to as epithelial cells.
  • This Phase I clinical trial leverages the Hoag Family Cancer Institute and Pickup Family Neurosciences Institute's assets in their collaboration when treating all aspects of brain tumors.
  • The study will be conducted by Hoag's Neuro-Oncology Clinic that helps guide the entire continuum of comprehensive care for patients with brain tumors.
  • "By offering our patients access to targeted immunotherapy, we expand our toolkit to include a treatment option that has the potential to turn the tables on brain cancer."

INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo® (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12 Months Following Treatment

Thursday, May 14, 2020 - 12:00pm

These data will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.

Key Points: 
  • These data will be featured at an oral poster presentation at the ASCO 2020 Virtual Scientific Program, May 29-31, 2020.
  • Currently, the median overall survival with standard of care therapy, which includes radiation and chemotherapy (temozolomide: TMZ), is approximately 15 to 22 months.
  • The Phase 1/2 clinical trial demonstrated that 84.4% percent (27 of 32) of patients with MGMT promoter unmethylated tumors, and 85% (17 of 20) of patients with MGMT promoter methylated tumors were alive at 12 months.
  • The majority of patients tested had a T cell immune response to one or more tumor-associated antigens encoded by INO-5401.

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Wednesday, May 13, 2020 - 3:10pm

GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.

Key Points: 
  • GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.
  • Approval of Optune for GBM in Greater China extends the promise of Tumor Treating Fields therapy to patients in the worlds largest market.
  • Approximately 1.5 million patients a year in China are diagnosed with non-small cell lung cancer, pancreatic cancer, ovarian cancer and gastric cancer, collectively.
  • Optune was recommended with Level 1 evidence as a treatment for newly diagnosed GBM patients in Chinas Glioma Treatment Guideline in 2018, and we are excited to now have Optune available as part of the standard of care for GBM patients in China.

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Wednesday, May 13, 2020 - 2:39pm

GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.

Key Points: 
  • GBM is the most common form of primary brain cancer, and Optune is the first treatment for glioblastoma approved in China in over 15 years.
  • Approval of Optune for GBM in Greater China extends the promise of Tumor Treating Fields therapy to patients in the worlds largest market.
  • Optune is intended as a treatment for adult patients (22 years of age or older) with recurrent supratentorial glioblastoma multiforme (GBM) diagnosed by histopathology or imaging, and newly diagnosed supratentorial GBM.
  • Optune with temozolomide (TMZ) is indicated for the treatment of adult patients with newly diagnosed GBM after surgery and radiotherapy.

Plus Therapeutics Announces Patient-Focused Presentation Supporting Brain Tumor Awareness Month

Tuesday, May 12, 2020 - 1:57pm

Plus Therapeutics is participating in the presentation as part of its recognition of Brain Tumor Awareness Month.

Key Points: 
  • Plus Therapeutics is participating in the presentation as part of its recognition of Brain Tumor Awareness Month.
  • Every May, a number of events and activities take place across the nation to raise awareness of the fight against brain tumors.
  • The Musella Foundation is a 501(c)(3) nonprofit public charity dedicated to helping brain tumor patients through emotional and financial support, education, advocacy and raising money for brain tumor research.
  • Plus Therapeutics is a clinical-stage pharmaceutical company focused on making a positive impact on patients lives and adding value to the healthcare system.

Children’s Brain Tumor Foundation (CBTF) to Host “May Matters 24-Hour Webathon”

Tuesday, May 12, 2020 - 2:00pm

There will be updates on advances in brain tumor research funded by CBTF, overviews of life during, and after a brain tumor and CBTF services.

Key Points: 
  • There will be updates on advances in brain tumor research funded by CBTF, overviews of life during, and after a brain tumor and CBTF services.
  • The goal of the Webathon is to share the talents, stories, and accomplishments of childhood brain tumor families and friends, along with donated performances by professional entertainers.
  • Money raised by CBTF funds vital brain tumor research through the brain tumor tissue consortium located at Children's Hospital of Philadelphia, scholarships, conferences, retreats, and support groups for patients, survivors, and their families.
  • You may find more information about the Children's Brain Tumor Foundation at http://cbtf.org/ .